"Hirudins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
| Descriptor ID |
D006629
|
| MeSH Number(s) |
D12.644.861.060.875 D12.776.872.060.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hirudins".
Below are MeSH descriptors whose meaning is more specific than "Hirudins".
This graph shows the total number of publications written about "Hirudins" by people in this website by year, and whether "Hirudins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 7 | 9 | 16 |
| 2018 | 3 | 7 | 10 |
| 2019 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hirudins" by people in Profiles.
-
Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination. Ann Emerg Med. 2021 10; 78(4):511-514.
-
Reply: Pitfalls of Unfractionated Heparin Use During ST-Segment Elevation Myocardial Infarction in Patients With COVID-19 Infection. J Am Coll Cardiol. 2021 01 05; 77(1):105-106.
-
Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Sep 07; 21(1):769.
-
Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19. J Cardiothorac Vasc Anesth. 2021 Apr; 35(4):1149-1153.
-
Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. Eur Heart J Cardiovasc Imaging. 2019 Dec 01; 20(12):1418-1428.
-
Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response. Ren Fail. 2019 Nov; 41(1):104-112.
-
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. Transfusion. 2019 06; 59(6):1924-1933.
-
Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. Cardiol J. 2019; 26(1):1-7.
-
Comparison of the antiplatelet and antithrombotic effects of bivalirudin versus unfractionated heparin: A platelet substudy of the HEAT PPCI trial. Thromb Res. 2018 12; 172:36-43.
-
The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome. Cardiovasc Revasc Med. 2018 12; 19(8):912-916.